louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00301015: Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers
Official title: Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Uncomplicated Plasmodium Falciparum Malaria
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
Collaborators: name: Muhimbili University of Health and Allied Sciences
First posted: 2006-03-10
Enrollment: 3005
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the efficiency of a rapid diagnostic test (Paracheck Pf) for the diagnosis of uncomplicated Plasmodium falciparum malaria by community health workers at village level in Tanzania and how the use of rapid diagnostic test may influence prescription of antimalarial drugs.

The hypothesis is that rapid diagnostic tests used by community health workers will reduce the use of antimalarial drugs (Coartem; Novartis) by 30% without affecting the health outcome.


Eligibility criteria: Inclusion Criteria:

* Fever
* Informed consent

Exclusion Criteria:

* Severe clinical manifestations, which require immediate referral
* Pregnancy
* Previous enrollment in the study within the last 28 days

Primary outcomes:
measure: Number of patients with fever prescribed artemether-lumefantrine for the treatment of malaria in respective study groups
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Kibaha
country: Tanzania
facility: Villages
state: Kibaha District
Study officials:
affiliation: Dept of Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden
name: Anders Björkman, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Mubi M, Janson A, Warsame M, Martensson A, Kallander K, Petzold MG, Ngasala B, Maganga G, Gustafsson LL, Massele A, Tomson G, Premji Z, Bjorkman A. Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: randomised cross-over trial in Tanzania. PLoS One. 2011;6(7):e19753. doi: 10.1371/journal.pone.0019753. Epub 2011 Jul 5.
Clinical trial NCT06136715: Massive Transfusion in Trauma Patient Registry
Official title: Massive Transfusion in Trauma Patient Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Trauma
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2023-11-18
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: ≥18 years old

* Included in the MDMC trauma registry
* Flagged for MTP activation and/or \>1U blood product recorded in the first 24 hours

Brief summary: The early use of blood products as a part of Massive Transfusion Protocol (MTP) during trauma resuscitation has been increasingly supported by providers and backed by the literature. However, the incidence of hypocalcemia during MTP has also been recorded and continues to be studied as an exacerbating factor in coagulopathy during trauma.

Detailed description: Although initially it was thought that the coagulopathy was due to the trauma itself, studies suggest that it is worsened by the transfusion of blood as this is associated with increased hypocalcemia. The level of hypocalcemia is said to correlate with the amount of blood products transfused, but the number of units needed to produce a particular degree of hypocalcemia remains to be defined. A standardized value for hypocalcemia due to MTP has yet to be established. Establishing this value would be helpful in determining what level actually affects the rate of mortality. Some studies suggest intravenous calcium supplement should be considered during massive transfusion while others state this does not make a difference.

This data repository will serve as a means to aggregate and analyze best practices as relative to MTP in the trauma patient, with specific interest in component best practices, whole blood protocols, and electrolyte/metabolite replacement.

Eligibility criteria: Inclusion Criteria:

* • ≥18 years old

  * Included in the Methodist dallas medical center(MDMC) trauma registry
  * Flagged for MTP activation and/or \>1unit(U) blood product recorded in the first 24 hours

Exclusion Criteria:

* • \<18 years old

Primary outcomes:
measure: Establish a data set that will be permissive of quality improvement studies/observations specific to MTP in the trauma patient.
timeFrame: 5 YEARS
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Methodist Dallas Medical Center
state: Texas
Study officials:
affiliation: Methodist Midlothian Medical Center
name: Conner McDaniel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00930215: Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males
Official title: Open Label, Randomized, Single Center, 2-way Crossover Bioequivalence Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule 40 mg D961H After Repeated Oral Administration in Japanese Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy volunteer
Japanese males
homo-EM
Bioequivalence study
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-06-30
Enrollment: 48
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The purpose of the study is to determine whether the HPMC capsule of D961H 40 mg is bioequivalent to gelatine capsules of D961H 40 mg after a steady state is reached on Day 5


Eligibility criteria: Inclusion Criteria:

* Healthy Japanese
* Classified as homo-EM
* Negative for HIV, Hepatitis B, Hepatitis C and syphilis

Exclusion Criteria:

* Significant clinical illness from 2 weeks preceding the pre-entry visit to the randomization
* Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease

Primary outcomes:
measure: Confirm the HPMC capsule of D961H 40 mg is bioequivalent to the gelatin capsule of D961H 40 mg by assessment of area under the plasma concentration-time curve at steady state on Day 5
timeFrame: PK sample at Day 5 of treatment period 1 and treatment period 2
Secondary outcomes:
measure: Evaluate the PK properties of HPMC capsule of D961H 40 mg following repeated oral doses, by assessment of plasma concentrations, mean residence time, time to maximum plasma concentration and half-life on Day 5
timeFrame: PK sample on Day 5 of treatment period 1 and treatment period 2
measure: Evaluate the safety and tolerability of HPMC capsule of D961H 40 mg by assessment of AEs, clinical lab tests, ECG, vital signs.
timeFrame: Pre-entry, Day 5 of treatment period 1 and treatment period 2 and follow up (5-7 days after last dose)
Other outcomes:
Locations:
city: Fukuoka
country: Japan
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: Takenobu Masaoka
role: STUDY_CHAIR
affiliation: AstraZeneca KK
name: Masataka Date
role: STUDY_DIRECTOR
affiliation: Kyushu Clinical Pharmacology Research Clinic
name: Shunji Matsuki
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01296815: Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Official title: Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Kaposi´s Sarcoma
Keywords: Kaposi sarcoma
HIV
Bevacizumab
Lead sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico
Sponsor class: OTHER_GOV
First posted: 2011-02-16
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Kaposi sarcoma remains the most common malignancy among persons with HIV.

Lesions localized to the airway may cause bleeding, pain and dyspnea.

New therapeutic approaches for local disease are needed.

The purpose of this study is to compare the effectiveness of intralesional bevacizumab + HAART vs HAART alone in treating localized Kaposi´s sarcoma of the airway in patients with AIDS.

Detailed description: Once disseminated disease is excluded, histologically confirmed HIV-positive patients with localized Kaposi's sarcoma of the airway will be randomized to receive HAART only or HAART + intralesional bevacizumab.

The primary outcome will be the size of lesions according to RECIST criteria. Patients in the HAART + bevacizumab arm will undergo series of 3 bevacizumab injections of 5 mg/cm3. Follow-up will be carried out through scheduled meetings for office setting examination every week for the first 8 weeks, then every 15 days for two months and finally every month for eight months.

Size of the lesions will be assessed by an independent observer and adverse events will be recorded.

Eligibility criteria: Inclusion Criteria:

* HIV infected
* KS of the oral cavity, pharynx and larynx, histopathologically confirmed
* HIV treatment-naïve

Exclusion Criteria:

* Airway obstructive lesions
* Actively bleeding lesions
* Tumor-associated oedema or ulceration
* Gastrointestinal KS
* KS in other nonnodal viscera

Primary outcomes:
measure: Number of Participants With Complete Response
timeFrame: 12 months
Secondary outcomes:
measure: Safety
timeFrame: 12 months
Other outcomes:
Locations:
city: Mexico
country: Mexico
facility: Centro de Investigacion en Enfermedades Infecciosas
Study officials:
affiliation: Centro de Investigacion en Enfermedades Infecciosas
name: Gustavo Reyes-Teran, M.D.
role: STUDY_DIRECTOR
affiliation: Centro de Investigacion en Enfermedades Infecciosas
name: Yuria Ablanedo-Terrazas, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ablanedo-Terrazas Y, Alvarado-de la Barrera C, Ormsby CE, Ruiz-Cruz M, Reyes-Teran G. Intralesional bevacizumab in patients with human immunodeficiency virus-associated Kaposi's sarcoma in the upper airway. Laryngoscope. 2015 Apr;125(4):E132-7. doi: 10.1002/lary.24988. Epub 2014 Oct 27.
Clinical trial NCT04275115: Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects
Official title: Interventional, Open-label, One-sequence Study to Investigate the Effects of Multiple Doses of Foliglurax on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Caffeine (CYP1A2), Montelukast (CYP2C8), and Midazolam (CYP3A4) in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2020-02-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to help determine which types of drugs that may interact with foliglurax

Detailed description: This study is designed to evaluate the PK of caffeine, montelukast and midazolam following multiple doses of foliglurax in healthy subjects. The study is divided into four periods:

* Period 1: investigation of the CYP450 probe substrates (caffeine, montelukast, midazolam) alone followed by a 2-day washout before start of Period 2.
* Period 2: administration of foliglurax for 7 days to reach steady state.
* Period 3: administration of the CYP450 probe substrates in combination with foliglurax followed by a 7-day washout before start of Period 4.
* Period 4: investigation of the effects of foliglurax on the PK of the CYP450 probe substrates following washout of foliglurax.

Eligibility criteria: Inclusion Criteria:

* Healthy men and women with a body mass index (BMI) of ≥ 18.5 and ≤ 30 kg/m2 and a minimum body weight of 60 kg for men and 50 kg for women.
* Women of child-bearing potential will have a confirmed non-pregnant and non-lactating status.

Exclusion Criteria:

* The subject has a regular intake of more than 500 mg of caffeine per day or impossibility to stop intake, on holidays for example, without headaches forcing to take caffeine again.

Other in- and exclusion criteria may apply

Primary outcomes:
measure: AUC0-inf
timeFrame: Day 1 and 11 for midazolam iv and Day 2,12 and 20 for oral cocktail probe substrates
measure: Cmax
timeFrame: Day 1 and 11 for midazolam iv and Day 2,12 and 20 for oral cocktail probe substrates
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Biotrial
Study officials:
affiliation: LundbeckClinicalTrials@Lundbeck.com
name: Email contact via H. Lundbeck A/S
role: STUDY_DIRECTOR
References:
Clinical trial NCT03440515: Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Official title: Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gastrointestinal Stromal Tumor(GIST)
Keywords: gastrointestinal stromal tumor
skin rash
imatinib
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2018-02-22
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may affect imatinib compliance. Our previous retrospective study suggested that severe skin rash induced by imatinib can be managed by systemic steroid without imatinib dose interruption or reduction. This phase II study was conducted to evaluate the efficacy and safety of systemic steroid in GIST patients with imatinib-associated severe skin rash.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older, at the time of acquisition of informed consent
* Histologically confirmed metastatic and/or advanced (unresectable or recurrent) GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene
* Patients with metastatic and/or advanced (unresectable or recurrent) GISTs, receiving imatinib as adjuvant or neo adjuvant, palliative chemotherapy for pre-or post- operations
* imatinib-associated severe skin rash which was defined as grade 3 skin rash or grade 2 skin rash with pruritus over grade 2

Primary outcomes:
measure: treatment success rate
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Asan Medical Center
name: Yoon-Koo Kang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim EJ, Ryu MH, Park SR, Beck MY, Lee WJ, Lee MW, Kang YK. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. Oncologist. 2020 Nov;25(11):e1785-e1793. doi: 10.1634/theoncologist.2019-0953. Epub 2020 Jul 12.
Clinical trial NCT00785915: AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects
Official title: A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: AZD6765
Japanese and Caucasian Healthy Volunteers
Phase I study
Single and multiple Ascending Dose
Japanese volunteers
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-11-05
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects


Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI): 18 to 27 kg/m 2
* Female subjects must be postmenopausal for at least 1 year, surgically sterile, or using a reliable method of contraception at screening.
* Male subjects must be willing to use accepted contraceptive methods, avoid unprotected sex, and donating sperm until 3 months after drug administration.

Exclusion Criteria:

* Clinically relevant disease and/or abnormalities (past or present)
* Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis at screening as judged by the investigator
* Use of any prescription medication within 14 days of Day 1
* Use of over-the-counter (OTC) medication (with the exception of acetaminophen), vitamin/nutritional supplements and herbal preparations within 14 days of Day 1
* Smoking in excess of 5 cigarettes per day or the equivalent within 28 days of Day 1

Primary outcomes:
measure: Safety and tolerability; Adverse events (AEs), vital signs, physical examinations, ECGs and clinical laboratory assessments
timeFrame: During the study
Secondary outcomes:
measure: Pharmacokinetic - Pharmacokinetic parameters for AZD6765 in plasma and urine
timeFrame: During residential period
measure: Genetics; Collect blood samples for optional exploratory genetic studies focusing on identification of genes that influence the disposition, efficacy, safety and tolerability of AZD6765.
timeFrame: During the study
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Research Site
state: California
city: Baltimore
country: United States
facility: Research Site
state: Maryland
Study officials:
affiliation: California Clinical Trials
name: Mark Yen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02752815: Reduced Chemotherapy in Low Risk DLBCL
Official title: Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Diffuse Large B-cell Lymphoma
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2016-04-27
Enrollment: 290
Sex: ALL
Minimum age (years): 14
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed de novo diffuse large B-cell lymphoma, complete response after 4 cycles of standard R-CHOP21
* Age\>=14 y.o.,\<=75 y.o.
* IPI=0-1
* non-bulky (largest diameter \<7.5cm)
* ECOG =0-1
* Life expectancy\>6 months
* Informed consented

Exclusion Criteria:

* Chemotherapy before
* Stem cell transplantation before
* History of malignancy, except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
* Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease
* Primary cutaneous, CNS DLBCL
* LVEF≤50%
* Other uncontrollable medical condition that may that may interfere the participation of the study
* Lab at enrollment(unless caused by lymphoma) Neutrophile\<1.5\*10\^9/L Platelet\<80\*10\^9/L Hemoglobulin\<100g/L ALT or AST \>2\*ULN,AKP or bilirubin \>1.5\*ULN Creatinine\>1.5\*ULN
* Not able to comply to the protocol for mental or other unknown reasons
* Pregnant or lactation
* If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.
* HIV infection

Primary outcomes:
measure: Progression free survival
timeFrame: 2-year
Secondary outcomes:
measure: Overall survival
timeFrame: 2-year
measure: Complete Response rate
timeFrame: 21 days after 8 cycles of treatment（each cycle is 21 days）
measure: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
timeFrame: Each cycle of treatment（each cycle is 21 days）and then every 3 months for 2 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Ruijin Hospital
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Weili Zhao, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00051415: Safety and Effectiveness of Flaxseed for Reducing High Cholesterol
Official title: A Double Blind, Randomized, Placebo Controlled Trial of Flaxseed in Patients With Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hypercholesterolemia
Keywords: Flaxseed
Cholesterol
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2003-01-15
Enrollment: 60
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Flaxseed, a rich source of fiber, may be a significant component of a cholesterol-reducing diet. The purpose of this study is to evaluate the safety and effectiveness of flaxseed in reducing high cholesterol.

Detailed description: Hypercholesterolemia is an established risk factor for atherosclerotic cardiovascular disease (ASCVD). The National Cholesterol Education Program estimates that 65 million Americans with hypercholesterolemia could be treated with diet and exercise alone. Flaxseed is a potential component of cholesterol-reducing diet regimens. Flaxseed contains significant amounts of soluble fiber and is a rich source of both alpha-linolenic acid and phytoestrogenic ligands, which have been implicated in the prevention of ASCVD. However, flaxseed's phytoestrogenic ligands may have undesirable hormonal effects. This study will systematically evaluate the safety and efficacy of ground flaxseed ingestion in both men and women with hypercholesterolemia.

Participants will be randomized to receive flaxseed or a matching wheat bran control. The test dose of flaxseed will be 40 grams administered in baked products (muffins, bread, or bars). The first 6 study weeks are a diet stabilization phase, followed by a 10-week study phase in which participants are expected to eat two servings of the test food daily. Blood and urine are collected for analysis, which will include measurement of low density lipoprotein cholesterol (LDL-C), post-prandial triglycerides, and urinary isoprostane secretion.

Eligibility criteria: Inclusion Criteria

* Men over 45 and post-menopausal women
* LDL cholesterol \> 130 mg/dl

Exclusion Criteria

* Established heart, kidney, or liver disease
* Diabetes
* Cancer

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Philippe O Szapary, MD
role: PRINCIPAL_INVESTIGATOR
References: